§Weight LossResearch protocol
MOTS-C.
MOTS-C is a 16‑amino-acid mitochondrial‑derived peptide encoded in the mtDNA 12S rRNA region[1][2]. Discovered in 2015, it enhances metabolic homeostasis through AMPK activation[1][3], increases sh...
Vial Size:
Research Use Only. PeptiJournal supports private research documentation and calculation support. It does not provide medical advice, human-use directions, or claims of safety or effectiveness.
Cited diluent3 mL
Cited protocol example—review and confirm.
Reference syringe capacity
Concentration
1,666.667
mcg/mL
Per event
500 mcg
7 events/week
Vials projected
14
8 cited weeks
Calculated volume reference
30.0 units
1mL syringe
MOTS-C
30.0u(0.300 mL)
Daily
Cited protocol & reconstitution guide
Source-backed reference fields by phase, including any volume fields authored in the cited guide.
Weeks 1–2
500 mcg (0.5 mg)
Units / volume30 units (0.30 mL)
Weeks 3–4
1000 mcg (1.0 mg)
Units / volume60 units (0.60 mL)
Weeks 5–6
1500 mcg (1.5 mg)
Units / volume90 units (0.90 mL)
Weeks 7–8
2000 mcg (2.0 mg)
Units / volume120 units (two 60‑unit injections)*
| Phase | Daily reference amount | Units / volume |
|---|---|---|
| Weeks 1–2 | 500 mcg (0.5 mg) | 30 units (0.30 mL) |
| Weeks 3–4 | 1000 mcg (1.0 mg) | 60 units (0.60 mL) |
| Weeks 5–6 | 1500 mcg (1.5 mg) | 90 units (0.90 mL) |
| Weeks 7–8 | 2000 mcg (2.0 mg) | 120 units (two 60‑unit injections)* |
Reconstitution by vial size
Calculated volume for each cited phase and vial variant. The highlighted column matches the selection above.
| Phase | 5 mg 3 mL water | 10 mg 3 mL water | 20 mg 3 mL water | 40 mg 3 mL water |
|---|---|---|---|---|
| Weeks 1–2 | 30 u 0.30 mL | 6 u 0.06 mL | 3 u 0.03 mL | 1.5 u 0.01 mL |
| Weeks 3–4 | 60 u 0.60 mL | 12 u 0.12 mL | 6 u 0.06 mL | 3 u 0.03 mL |
| Weeks 5–6 | 90 u 0.90 mL | 18 u 0.18 mL | 9 u 0.09 mL | 4.5 u 0.04 mL |
| Weeks 7–8 | — | 24 u 0.24 mL | 12 u 0.12 mL | 6 u 0.06 mL |
| Weeks 9–10+ | — | 30 u 0.30 mL | 15 u 0.15 mL | 7.5 u 0.07 mL |
Cited guide source: View source